Table 1.
Characteristics of HIV-1 infected patients according to specific subtypes
| Charact eristic |
No - Subt ype B (Tot al, N=1 06) |
02_ AG (N= 46) |
C (N= 15) |
A (N= 15) |
01_ AE (N= 6) |
06_ CPX (N= 5) |
14_ BG (N= 5) |
Oth er1 (N= 14) |
P val ue |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | |||||||||||||||||
| Male | 53 | 50% | 20 | 43% | 10 | 67% | 6 | 40% | 4 | 67% | 2 | 40% | 3 | 60% | 8 | 57% | 0.62 |
| Female | 53 | 50% | 26 | 57% | 5 | 33% | 9 | 60% | 2 | 33% | 3 | 60% | 2 | 40% | 6 | 43% | |
| Age at Diagnosis (years) | |||||||||||||||||
| 0–17 | 15 | 14% | 5 | 11% | 6 | 40% | 2 | 13% | 0 | 0% | 1 | 20% | 0 | 0% | 1 | 7% | 0.08 |
| 18–29 | 30 | 28% | 15 | 33% | 3 | 20% | 4 | 27% | 1 | 17% | 2 | 40% | 3 | 60% | 2 | 14% | 0.48 |
| 30–39 | 29 | 27% | 12 | 26% | 3 | 20% | 4 | 27% | 3 | 50% | 2 | 40% | 0 | 0% | 5 | 36% | 0.57 |
| 40–49 | 23 | 22% | 11 | 24% | 2 | 13% | 2 | 13% | 1 | 17% | 0 | 0% | 2 | 40% | 5 | 36% | 0.49 |
| >=50 | 7 | 7% | 2 | 4% | 0 | 0% | 3 | 20% | 1 | 17% | 0 | 0% | 0 | 0% | 1 | 7% | 0.28 |
| Unknown | 2 | 2% | 1 | 2% | 1 | 7% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0.84 |
| Transmission Risk2 | |||||||||||||||||
| MSM | 5 | 5% | 0 | 0% | 0 | 0% | 0 | 0% | 1 | 17% | 0 | 0% | 0 | 0% | 4 | 29% | <0.01 |
| MSF | 34 | 32% | 17 | 37% | 2 | 13% | 5 | 33% | 2 | 33% | 1 | 20% | 3 | 60% | 4 | 29% | 0.53 |
| FSM | 41 | 39% | 19 | 41% | 1 | 7% | 8 | 53% | 2 | 33% | 3 | 60% | 2 | 40% | 6 | 43% | 0.17 |
| IDU | 6 | 6% | 4 | 9% | 1 | 7% | 1 | 7% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0.85 |
| Perinatal | 11 | 10% | 3 | 7% | 6 | 40% | 1 | 7% | 0 | 0% | 1 | 20% | 0 | 0% | 0 | 0% | <0.01 |
| Unknown | 8 | 8% | 3 | 7% | 5 | 33% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0.006 |
| Other | 1 | 1% | 0 | 0% | 0 | 0% | 0 | 0% | 1 | 17% | 0 | 0% | 0 | 0% | 0 | 0% | 0.01 |
| Place of Birth | |||||||||||||||||
| Africa | 81 | 76% | 37 | 80% | 13 | 87% | 14 | 93% | 0 | 0% | 5 | 100% | 4 | 80% | 8 | 57% | <0.01 |
| Asia | 6 | 6% | 0 | 0% | 0 | 0% | 0 | 0% | 6 | 100% | 0 | 0% | 0 | 0% | 0 | 0% | |
| Europe | 1 | 1% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 1 | 7% | |
| Central America | 3 | 3% | 1 | 2% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 2 | 14% | |
| United States | 5 | 5% | 2 | 4% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 1 | 20% | 2 | 14% | |
| Unknown | 10 | 9% | 6 | 13% | 2 | 13% | 1 | 7% | 0 | 0% | 0 | 0% | 0 | 0% | 1 | 7% | |
| Treatment | |||||||||||||||||
| Naive | 67 | 63% | 29 | 63% | 8 | 53% | 9 | 60% | 3 | 50% | 3 | 60% | 3 | 60% | 12 | 86% | 0.64 |
| Residence | |||||||||||||||||
| Providence | 64 | 60% | 31 | 67% | 12 | 80% | 8 | 53% | 3 | 50% | 2 | 40% | 0 | 0% | 8 | 57% | 0.052 |
| Phylogeny | |||||||||||||||||
| Clusters | 21 | 20% | 4 | 9% | 8 | 53% | 2 | 13% | 0 | 0% | 2 | 40% | 2 | 40% | 3 | 20% | <0.01 |
1
Other refers to subtypes and recombinants with less than five sequences, including CRF24_BG(3), CRF43_02G(3), D(3), F1(1), G(3), CRF11_CPX(1).
2
Transmission risk: MSM=men who have sex with men; MSF=males who have sex with females; FSM=females who have sex with males; IDU=Injection drug use. ‘Other’ risk factor includes one transfusion–related infection.